Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06510491

Epcoritamab in Previously Treated WM

A Phase 2 Trial Investigating Epcoritamab in Patients With Previously Treated Waldenstrom Macroglobulinemia (WM)

Sponsor: Genmab

Conditions B-Cell Lymphoproliferative Disorder Waldenstrom Macroglobulinemia

Interventions Epcoritamab

Updated 4 times since 2024 Last updated: Mar 12, 2026 Started: Dec 6, 2024 Primary completion: Apr 30, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06510491, this PHASE2 trial focuses on B-Cell Lymphoproliferative Disorder and Waldenstrom Macroglobulinemia and remains actively recruiting participants. Sponsored by Genmab, it has been updated 4 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2
Jan 2025 — Mar 2026 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genmab
Gottfried von Keudell, MD PhD

Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Chapel Hill, United States